SPOTLIGHT: Akela faces delay

Akela Pharma says it's facing a delay developing Fentanyl Taifun for breakthrough cancer pain after the FDA rejected toxicology studies saying that deviations in Good Laboratory Practice had invalidated the results. Akela says that the decision won't delay its submission for regulatory approval by more than six months. Fentanyl Taifun is a formulation of Fentanyl delivered by Akela's Taifun inhaler technology. Release

Suggested Articles

Although BridgeBio has grown from one program to 21 within five years, it will present four top prospects to investors during an R&D day on Tuesday.

Dewpoint Therapeutics aims to advance research in one of the more mysterious cell organelles: biomolecular condensates.

The FDA slapped a partial clinical hold on the phase 2/3 study of Inovio’s COVID-19 vaccine because it has “additional questions” about the trial.